He takes over the chairmanship of Karolinska Development
Av Ella Käck
The board of Karolinska Development has appointed Ben Toogood, a board member since 2021, as chairman until the next annual general meeting, according to a press release
Ben Toogood, the CEO of the pharmaceutical company Invox, brings over 25 years of experience in the pharmaceutical industry, having worked at companies such as Novartis and Aspen Pharmacare.
He succeeds Professor Hans Wigzell, who stepped down from the position at his own request, as announced on December 11.
No specific reason has been given for Wigzell's decision to resign. He has served multiple terms as Chairman since the company’s founding.
The announcement came shortly after Karolinska Development revealed a cost-saving program aimed at reducing personnel expenses by 20 percent, as previously reported by Life Science Sweden tidigare rapporterat.
Karolinska Development, founded in 2003, is an investment company focused on developing medical innovations from research conducted at the Karolinska Institute and other nordic universities. The company’s portfolio currently includes eleven companies involved in pharmaceutical development.
Artikeln är en del av vårt tema om News in English.